EntryPoint Capital’s Ionis Pharmaceuticals IONS Stock Holding History
Bought
Maintained
Sold
Other funds holding IONS
EntryPoint Capital's IONS Position: Q2 2026 in Review
EntryPoint Capital sold out of Ionis Pharmaceuticals (IONS) in Q2 2026, closing a stake of 2,963 shares — an estimated $222K sold.
EntryPoint Capital first reported a position in IONS in Q4 2023 and held it in 5 quarters. The position peaked at $226K in Q3 2025. 514 funds tracked by Wall St. Rank hold IONS as of Q2 2026.
- EntryPoint Capital reported no remaining Ionis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
- EntryPoint Capital sold 2,963 Ionis Pharmaceuticals shares in Q2 2026, an estimated $222K.
- EntryPoint Capital first reported a position in Ionis Pharmaceuticals in Q4 2023 and held it in 5 quarters.
- EntryPoint Capital's Ionis Pharmaceuticals position peaked at $226K in Q3 2025.
- 514 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2026.
Based on EntryPoint Capital's 13F filing for Q2 2026, filed 13 Aug 2026.